Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the University of Kentucky.

Geographic atrophy is a subtype of advanced age-related macular degeneration (AMD). It causes blind spots in the center of vision and a permanent loss of visual sharpness. AMD progresses through ...

Two reading metrics outperform 2 existing reading metrics for determining functional decline in patients with geographic atrophy.

The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

Opens in a new tab or window Geographic atrophy (GA) progressed more often in patients with better baseline vision and those with lesions closer to the foveal center, according to a study that ...

The FDA has expanded the labeling for Izervay (avacincaptad pegol) to include longer-term administration for geographic ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ ...

An occupational therapist specializing in low vision offers tips to help you adapt to vision loss from geographic atrophy.

In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.